
Quest Diagnostics (NYSE: DGX) And Mainz Biomed (NASDAQ: MYNZ) Team Up To Commercialize ColoAlert Early Cancer Detection Screening In The U.S.
Published on December 20, 2024
in early cancer detection and prevention. With $8 million in funding dedicated to expediting FDA approval, this initiative aims to rapidly
Other news
